These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17476758)

  • 1. [Treatment of multiple myeloma with thalidomide and immunomodulatory drugs].
    Hattori Y
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():596-600. PubMed ID: 17476758
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of multiple myeloma by immunomodulatory drugs].
    Hata H
    Rinsho Ketsueki; 2011 Oct; 52(10):1485-95. PubMed ID: 21971225
    [No Abstract]   [Full Text] [Related]  

  • 4. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
    Anderson KC; Prince HM
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
    [No Abstract]   [Full Text] [Related]  

  • 5. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Despite potential side effects, two drugs make a comeback.
    Bjorn G
    Nat Med; 2008 Mar; 14(3):226. PubMed ID: 18323826
    [No Abstract]   [Full Text] [Related]  

  • 10. Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
    Lacy MQ; Rajkumar SV
    Am J Hematol; 2010 Feb; 85(2):95-6. PubMed ID: 20095057
    [No Abstract]   [Full Text] [Related]  

  • 11. Disseminated keratotic spicules: a rare manifestation in multiple myeloma and successful response to lenalidomide.
    Vivas AC; Chimento SM; Herschthal J; Spock C; Alonso-Llamazares J
    J Am Acad Dermatol; 2013 Jun; 68(6):e179-80. PubMed ID: 23680209
    [No Abstract]   [Full Text] [Related]  

  • 12. Pomalidomide (Pomalyst) for multiple myeloma.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988965
    [No Abstract]   [Full Text] [Related]  

  • 13. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide: present and future in multiple myeloma.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-generation immunomodulatory drugs in leptomeningeal myeloma.
    Bohn JP; Willenbacher W; Peschel I; Oberacher H; Steurer M
    Leuk Lymphoma; 2019 Feb; 60(2):550-552. PubMed ID: 30032690
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanism of immunomodulatory drugs in multiple myeloma.
    Sedlarikova L; Kubiczkova L; Sevcikova S; Hajek R
    Leuk Res; 2012 Oct; 36(10):1218-24. PubMed ID: 22727252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
    Raje N; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
    Zago M; Adam P; Goldschmidt H; Fend F; Kanz L; Weisel K
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e7-e11. PubMed ID: 24169269
    [No Abstract]   [Full Text] [Related]  

  • 19. Lenalidomide mode of action: linking bench and clinical findings.
    Davies F; Baz R
    Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.